Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ACE-86225106 dose-escalation monotherapy in advanced solid tumors
CTR20240158Phase 2Active
- Sponsor
- U-Link Pharma
- Start
- Mar 2024
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ACE-86225106 in Non-hematologic malignancy, ovarian cancer and prostate cancer (PCa), sponsored by U-Link Pharma. Primary endpoints: AE/SAE incidence, Dose-limiting toxicities (DLTs) and 1 more. Started Mar 2024; status: active.
02
Drugs
ACE-86225106
03
Conditions
Non-hematologic malignancyovarian cancerprostate cancer (PCa)
Beyond the preview
Go deeper on CTR20240158.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20240158.